Daridorexant

Introduction Overview

Generic Name

daridorexant

Brand Name

Quviviq

Dosage Form

oral tablet

Drug Class

Miscellaneous anxiolytics, sedatives and hypnotics (Orexin receptor antagonist)

Pharmacokinetics

Absorption:
Daridorexant is rapidly absorbed following oral administration, with peak plasma concentrations typically reached within approximately 1 to 2 hours. The rate of absorption may be slowed if taken with food, which can delay the onset of therapeutic effects by extending the time to reach peak levels. This pharmacokinetic characteristic is clinically important when timing the dose to optimize sleep induction.

Distribution:
After absorption, daridorexant demonstrates moderate plasma protein binding (~99.7%), primarily to albumin and alpha-1-acid glycoprotein, facilitating wide distribution throughout the body including the central nervous system. The volume of distribution is estimated to be moderate, supporting adequate CNS penetration necessary for its mechanism of action. Distribution may be affected by factors such as body mass and plasma protein levels.

Metabolism:
Daridorexant undergoes extensive metabolism primarily via the liver cytochrome P450 enzyme CYP3A4. Its biotransformation results in inactive metabolites that are mainly excreted renally and fecally. The metabolic pathway signifies potential for drug-drug interactions with compounds that inhibit or induce CYP3A4, affecting plasma levels and therapeutic efficacy.

Elimination:
The elimination half-life of daridorexant ranges approximately 8 to 10 hours, supporting once-nightly dosing aligned with sleep cycles. Excretion occurs predominantly through the feces (~57%) and to a lesser extent in the urine (~38%) as metabolites. Renal impairment has a limited effect on clearance, but severe hepatic impairment is expected to alter drug elimination, necessitating dosage adjustments or use caution. Accumulation is minimal, even with repeated dosing, minimizing concerns regarding prolonged sedation.

Dosage Forms

Available Dosage Forms:
Quviviq is available exclusively as oral tablets designed for once-daily evening administration. The formulation includes film-coated tablets available in two strengths:
- 25 mg daridorexant hydrochloride
- 50 mg daridorexant hydrochloride

The tablets contain daridorexant as the active ingredient along with excipients such as croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, povidone, and silicon dioxide. The film coating includes glycerin, hypromellose, iron oxide pigments (black, red, and yellow for 50 mg), talc, titanium dioxide, and microcrystalline cellulose.

Dosages for Adults and Adolescents:
The recommended dose for adults with insomnia is 25 mg to 50 mg taken orally once per night, within 30 minutes prior to bedtime. Patients are advised to ensure that at least 7 hours remain before the intended time to awaken to reduce risks of next-day impairment. Dose titration or adjustments should be individualized based on efficacy and tolerability.
Quviviq is not indicated for use in pediatric populations, and safety and efficacy in children have not been established.

Specific Patient Populations:
- Elderly: No specific dosage adjustment recommended solely based on age; however, caution is advised due to increased sensitivity to sedatives.
- Hepatic impairment: Use with caution in patients with moderate hepatic impairment; dosage adjustment or alternative therapy may be considered. Quviviq is not recommended in severe hepatic impairment due to altered metabolism.
- Renal impairment: No adjustment required for mild to moderate renal impairment; severe impairment has limited data but presumed safe with caution.
- Pregnant and breastfeeding women: Safety not established; usage only if clearly needed and justified by potential benefit versus risk.

Clinical guidelines recommend administration only when patients can dedicate at least 7 hours to sleep to avoid adverse cognitive and motor effects.

Mechanism Of Action

Quviviq (daridorexant) is a first-in-class dual orexin receptor antagonist (DORA) specifically targeting both orexin receptor type 1 (OX1R) and orexin receptor type 2 (OX2R). Orexins are neuropeptides produced in the hypothalamus that play a crucial role in promoting wakefulness and arousal by stimulating various monoaminergic and cholinergic pathways in the central nervous system.

By selectively and reversibly binding to OX1R and OX2R, daridorexant inhibits orexin-mediated signaling pathways, thereby suppressing the wake drive. This promotes the natural transition into sleep and facilitates the maintenance of sleep without impairing the overall sleep architecture significantly. Unlike traditional sedative-hypnotics that act on gamma-aminobutyric acid (GABA) receptors, Quviviq preserves cognitive and psychomotor functioning by targeting the upstream orexin system.

At the cellular level, orexin neurons project to multiple wake-promoting regions, including the locus coeruleus, tuberomammillary nucleus, and raphe nuclei. Daridorexant's blockade of orexin receptors reduces excitatory neurotransmission and neuronal firing in these areas, leading to decreased cortical arousal. This mechanism is supported by clinical polysomnographic studies showing increased total sleep time and decreased wake after sleep onset in patients with insomnia.

Compared to benzodiazepines and nonbenzodiazepine ‘Z-drugs,’ Quviviq exhibits a distinct pharmacodynamic profile, avoiding the drawbacks of tolerance, dependence, and alteration of sleep stages. Its unique action on orexin receptors represents an advancement in insomnia management, with ongoing research evaluating long-term safety and efficacy.

Pharmacological Actions

Dual antagonism of orexin receptors OX1R and OX2R leading to inhibition of wakefulness-promoting neuropeptides.
Promotion of sleep initiation and sleep maintenance by decreasing arousal signals within the central nervous system.
Preservation of normal sleep architecture without significant disruption of REM or non-REM sleep stages.
Selective targeting of the wakefulness system rather than generalized CNS depression, minimizing cognitive impairment.
Reduction of sleep latency and improvement in total sleep duration in adults with insomnia.
Minimal development of tolerance or physical dependence compared to traditional hypnotic agents.
Limited effect on respiratory drive, making it potentially safer in patients with mild respiratory disorders.
No significant impact on weight or metabolic parameters based on clinical study data.
Abuse potential is lower relative to benzodiazepines but still classified as Schedule IV controlled substance.
Rapid onset of action with sleep-promoting effects observed within approximately 30 minutes post-dose.
Metabolized primarily via CYP3A4, allowing predictable drug interactions monitoring.

Therapeutic Or Clinical Uses

Treatment of adult patients with insomnia characterized by difficulty in sleep onset and/or sleep maintenance.
Management of chronic insomnia symptoms requiring pharmacologic intervention when non-pharmacologic treatments are insufficient.
Facilitation of improved sleep quality and duration without adverse alterations in sleep architecture.
Potential off-label consideration for improving sleep disturbance secondary to psychiatric disorders under clinician discretion.
Alternative option for patients intolerant to benzodiazepines or non-benzodiazepine hypnotics.
Adjunct therapy in patients with coexisting conditions where sedation by traditional hypnotics is contraindicated.
Use in adults requiring maintenance of daytime functioning with minimized next-day sedation risks.
Support for long-term insomnia management as evidenced by clinical trial data up to one year.
Utility in patients with history of substance abuse is evaluated cautiously owing to its Schedule IV status.
Treatment of patients with normal hepatic and renal function, with dose modification considerations in impairment cases.
Sleep promotion in patients who require a novel pharmacologic approach targeting the orexin system.

Side Or Adverse Effects

Common: headache, occurring with mild to moderate intensity.
Somnolence or excessive sleepiness during the day following nocturnal dosing.
Fatigue and dizziness reported less frequently but clinically relevant in some patients.
Risk of complex sleep behaviors, including sleepwalking, sleep-driving, and other activities performed while not fully awake.
Temporary episodes of sleep paralysis and hypnagogic or hypnopompic hallucinations during sleep onset or awakening.
Potential worsening of depression or emergence of suicidal ideation necessitating close monitoring in susceptible individuals.
Daytime impairment of alertness and decreased psychomotor functioning, particularly if dosing is mistimed.
Potential next-day impairment of driving ability and operating machinery if full night’s sleep not achieved.
Low incidence of gastrointestinal disturbances such as nausea or dry mouth.
Rare allergic reactions including rash or hypersensitivity.
No significant weight gain or metabolic adverse events documented in controlled clinical studies.
Minimal reports of withdrawal symptoms or rebound insomnia observed upon discontinuation.
Abuse and dependence potential though lower than benzodiazepines; caution advised in patients with abuse history.
Cognitive or memory disturbances are uncommon but warrant monitoring in elderly or polypharmacy patients.
No clinically significant impact on respiratory function at therapeutic doses.

Precautions

Use Quviviq only when patients can dedicate at least 7 hours for uninterrupted sleep to avoid next-day impairment.
Monitor patients with a history of depression, suicidal ideation, or other psychiatric disorders closely during treatment.
Avoid use in patients with narcolepsy or cataplexy due to orexin system involvement in these conditions.
Exercise caution when co-administered with other CNS depressants, including alcohol, sedating antihistamines, benzodiazepines, or muscle relaxants.
Dose adjustments or avoidance may be necessary in moderate to severe hepatic impairment.
Assess potential for abuse and dependence, especially in patients with prior substance use disorder.
Advise patients regarding the risk of complex sleep behaviors and instruct to discontinue if such behaviors develop.
Inform patients about the risk of daytime somnolence and impaired driving or operating machinery.
Pregnancy and breastfeeding use only if potential benefits justify potential risks; limited human data available.
Caution in elderly patients due to increased sensitivity to sedatives and risk of falls or cognitive impairment.
Avoid concomitant use with strong CYP3A4 inhibitors or inducers without medical supervision.
Instruct patients not to take larger doses or more frequent doses than prescribed.
Ensure appropriate storage out of reach of children due to abuse liability.
Evaluate patient’s complete medication regimen to prevent harmful drug interactions.
Consider alternative treatment if patient reports intolerable adverse effects or insufficient clinical benefit.

Warnings

Quviviq may cause next-day impairment of alertness and driving ability, especially if a full 7 hours of sleep has not been attained.
Do not take Quviviq with alcohol or other CNS depressants due to additive sedative effects.
Risk of complex sleep-related behaviors such as sleepwalking, sleep-driving, and other activities performed while not fully awake without recall.
Potential for serious psychiatric adverse events, including worsening depression and suicidal ideation.
Use is contraindicated in patients with narcolepsy due to the drug’s orexin receptor antagonism.
Avoid exceeding prescribed doses; overdose can lead to excessive sedation and other serious CNS effects.
Quviviq is a Schedule IV controlled substance with the potential for abuse and dependence.
Pregnancy safety not established; use only when clearly needed and after considering potential risks.
Discontinue Quviviq promptly if complex sleep behaviors or hallucinations occur.
Caution advised when used in patients with respiratory impairment, including sleep apnea.
Vigilance needed in patients with hepatic impairment as clearance may be reduced.
Alert patients not to drive or engage in hazardous activities until they know how Quviviq affects them.
Risk of sleep paralysis and transient hallucinations may occur, requiring clinical attention.
Not recommended for use in pediatric population; safety and efficacy not established.
Storage should prevent unauthorized access due to risk of misuse or diversion.

Contraindication

Known hypersensitivity to daridorexant or any of the inactive ingredients in Quviviq.
Patients diagnosed with narcolepsy or conditions characterized by sudden onset sleep episodes.
Concurrent use with other orexin receptor antagonists or hypnotic agents with overlapping sedative actions is recommended against.
Severe hepatic impairment due to altered drug metabolism and clearance.
History of complex sleep behaviors linked to sedative medications unless benefits outweigh risks after careful consideration.
Pregnant or breastfeeding women unless no safer alternatives and benefits justify risks, as data on safety is insufficient.
Patients with significant untreated respiratory disorders or severe obstructive sleep apnea may be at increased risk.
Concurrent use with potent CYP3A4 inhibitors without dose adjustment, due to risk of elevated plasma levels.
Patients with known substance abuse disorders unless closely monitored owing to abuse potential.
Children and adolescents below 18 years of age due to lack of established safety and efficacy data.
Any condition which may be exacerbated by sedative or CNS depressant effects unless managed carefully.
Use in combination with alcohol due to increased sedation and risk of respiratory depression is contraindicated.
Unstable psychiatric disorders that may worsen with use of sedative-hypnotic agents without close supervision.
Existing hypersensitivity reactions to other orexin receptor antagonists may preclude Quviviq use.
Patients unable to ensure a contiguous block of at least 7 hours for sleep following dosing.

Drug Interactions

CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase plasma concentrations of daridorexant, necessitating dose adjustments.
CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce daridorexant levels, potentially decreasing efficacy.
Concomitant use with other CNS depressants (benzodiazepines, opioids, sedating antihistamines, muscle relaxants) can increase sedation and respiratory depression risk.
Alcohol potentiates sedative effects, increasing risk of impairment and complex sleep behaviors.
Drugs that prolong QT interval may require caution due to potential additive cardiac effects.
Combination with antidepressants that have sedating properties may exacerbate CNS depressive effects.
Antihypertensive agents may have enhanced hypotensive effects when combined with daridorexant.
Warfarin and other anticoagulants have no major known interactions but monitoring is advisable due to polypharmacy in insomnia patients.
Drugs metabolized by CYP3A4 with narrow therapeutic indices require caution due to competitive metabolism.
Herbal supplements such as St. John's Wort may decrease effectiveness by inducing CYP3A4.
Caution when combined with other hypnotics like zolpidem; simultaneous use is contraindicated.
Possible interactions with hormonal contraceptives potentially altering efficacy due to metabolism modulation.
No significant interaction with food except delayed absorption when taken with a high-fat meal.
Close monitoring advised when used with antiepileptic drugs sharing CYP3A4 metabolism.
Patients should inform healthcare providers of all prescription and over-the-counter medicines, vitamins, and supplements to avoid interactions.

Preparations Of The Drug

Film-coated oral tablets formulated with daridorexant hydrochloride as active pharmaceutical ingredient.
Available in two strengths: 25 mg and 50 mg tablets.
Inactive ingredients include croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, povidone, and silicon dioxide.
Tablet film coating contains glycerin, hypromellose, iron oxide black, iron oxide red, microcrystalline cellulose, talc, titanium dioxide, and in the 50 mg tablet, iron oxide yellow pigment.
Packaged in blister packs or bottles suitable for preservation of tablet integrity against moisture and light.
Manufactured in compliance with current Good Manufacturing Practices (cGMP) by Idorsia Pharmaceuticals US Inc.
Storage conditions specified as controlled room temperature between 68°F to 77°F (20°C to 25°C).
Kept securely out of reach of children and pets due to potential for misuse and overdose.
No generic formulations currently available; branded product only.
Prescribed for once-daily evening dosing within 30 minutes prior to bedtime.
Tablets are designed for oral administration with no special preparation required.
No known specialty compounded formulations recommended as standard treatment.
Packaging includes patient information leaflets outlining dosing instructions and safety warnings.
Disposal instructions emphasize preventing accidental ingestion and environmental safety.
Supply typically dispensed in 30-tablet quantities with prescription renewals as per medical guidance.